retatrutide phase 3 results Results: Trials, Safety, and NHS Outlook – Bolt Pharmacy Retatrutide Phase 3 Updates: Significant

Glucose transporter 1 deficiency syndrome and hemiplegic migraines as a dominant presenting clinical feature

Doses above 1.0mg daily do not increase melanogenesis proportionally but do raise the probability of off-target MC3R/MC4R activation, manifesting as nausea, spontaneous erections, or darkening of existing nevi

Diffraction data were collected up to 1.7 resolution for the complex crystals

doi: 10.1001/jama.2024.3073 Summary Keywords obesity, obesity pharmacotherapy, precision medicine, personalized treatment, combination therapy, weight management, weight loss Citation Steenackers N, Toumassian J, Deleus E, Mertens A, Lannoo M, Pazmino S, van Laar ADE, Van der Schueren B and Vangoitsenhoven R (2025) Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals

If you have questions about current weightloss treatments, our clinical team is here to help